UC-961 (Cirmtuzumab) in Relapsed or Refractory Chronic Lymphocytic Leukemia

计划入组 26 人 · 首次发布于 2014 年 8 月 21 日

Extension Study of UC-961 (Cirmtuzumab) for Patients With Chronic Lymphocytic Leukemia Treated Previously With UC-961

计划入组 3 人 · 首次发布于 2016 年 8 月 9 日

Study of Docetaxel Combined with Cirmtuzumab in Metastatic Castration Resistant Prostate Cancer

计划入组 6 人 · 首次发布于 2021 年 12 月 14 日

Cirmtuzumab Vedotin

Zilovertamab

Cirmtuzumab-ADC-7(VelosBio)

CENTRE INTERNATIONAL DE RECHERCHES MEDICALES DE FRANCEVILLE

Gabon

CIIM PLUS, d.o.o.

Slovenia

SORIN CRM SAS

France

CIRM Awards $4.7 Million to Advance AAV Gene Therapy for Blue Cone Monochromacy

ReviR Therapeutics Secures $4.6M CIRM Grant for Dual-Target Huntington's Disease Therapy

UCLA Secures $5.8M CIRM Grant for Pioneering Angelman Syndrome Gene Therapy Research